| C-SHALS 2009 will address a number of important discussion questions including: |
 |
| DAY 1 |
| Moderated Forum 1: BioMedicine |
- Tim Clark, Core Member, Harvard Initiative in Innovative Computing
- Parsa Mirhaji, MD, Director, The University of Texas Health Science Center
|
| DISCUSSION ISSUES:(Moderator: Eric Neumann) |
|
1. What are some of the information challenges in biomedical studies in different disease areas (e.g., Alzheimers and Cancer)? |
| |
2. Are medical record systems currently adequate for organizing patient info in support of the data analysis for your studies? |
| |
3. Do you see other researchers and doctors using the knowledge your capturing, and if so in what way? |
| |
|
| Moderated Forum 2: Semantic Web in Pharma |
- Dr. Philip Ashworth, UCB Pharma
- Ranga Chandra Gudivada, Eli Lilly and Company
- Jaime Melendez, Merck and Co., Inc.
- Therese Vachon, Novartis Pharma AG
|
| DISCUSSION ISSUES: (Moderator: Ted Slater) |
| |
1. What experiences did you have in integrating your projects with existing data systems? |
| |
2. What are some of the SW features that you found useful in the different apps? |
| |
3. Can you identify any common elements in your approaches that would be applicable cross all your cases? |
|
|
| Moderated Forum 3: Biomarkers & Compounds |
- Jonas S. Almeida, University of Texas
- Thomas N. Plasterer, PhD, BG Medicine
- Antony J. Williams, ChemZoo Inc.
|
| DISCUSSION ISSUES: (Moderator: Susie Stephens) |
|
1. Do you see your challenges as mostly data management or knowledge discovery? |
| |
2. Is sharing insights and models with other scientists an important part of your work? |
| |
3. How much of your goals involve numeric computation, and how much are related to symbolic processing and reasoning? |
|
|
| DAY 2 |
| Moderated Forum 4: Ontologies |
- Marco F. Ramoni, PhD, Harvard Medical School
- Larisa Soldatova, University of Wales
- Nigam Shah, Stanford University
|
| DISCUSSION ISSUES: (Moderator: Joanne Luciano) |
|
1. Do we need overarching high level ontologies before creating more specific ontologies? |
| |
2. What are some methodologies for bridging different existing ontologies |
| |
3. Should Thesauri be represented as complete ontologies, or using specialized models such as SKOS? |
|
|
| Moderated Forum 5: Knowledge Bases |
- Ted Slater, Pfizer
- Bruce Aronow, Ph.D., Cincinnati Children's Hospital Medical Center, University of Cincinnati
- Will Loging, Boehringer Ingelheim Pharmaceuticals, Inc.
|
| DISCUSSION ISSUES: (Moderator: Mike Bevil) |
|
1. How do you define what a knowledge base is, and how do you envision it being used by researchers? |
|
2. Do you differentiate between absolute factual knowledge, and proposed models? Does this require different ontological representations? |
| |
3. How do you see electronic knowledge becoming more wide-spread n R&D? Will it be a business differentiator and will it improve productivity? |
| |
|
